EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

Tuan H Vu, Renato Mantegazza, Djillali Annane, Masahisa Katsuno iD, Andreas Meisel iD, Michael W Nicolle, Vera Bril iD, Rasha Aguzzi, Glen Frick, James F Howard iD, CHAMPION MG Study Group

European Journal of Neurology · 2025-04 · 32 (4)

DOI: 10.1111/ene.70158 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 16.04.2025. Verfasst von Tuan H Vu und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida Morsani College of Medicine, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Autoantibodies, Myasthenia Gravis, Receptors, Cholinergic. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ravulizumab, an anti‐complement C5 monoclonal antibody, was efficacious with acceptable safety in the randomized controlled period (RCP) and interim open‐label extension (OLE) periods of the CHAMPION MG phase 3 trial in adults with anti‐acetylcholine receptor antibody‐positive (AChR‐Ab+) generalized myasthenia gravis (gMG). Here, we report final results from the OLE.

Methods

Patients who completed the 26‐week RCP could enter the OLE and receive ravulizumab for up to 4 years. Efficacy and safety were assessed throughout the OLE.

Results

Among all ravulizumab‐treated patients ( n = 169; median [range] ravulizumab treatment, 759.0 [14.0, 1265.0] days), 161 entered the OLE (ravulizumab‐ravulizumab: n = 78; placebo‐ravulizumab: n = 83). Sustained improvements were observed in Myasthenia Gravis Activities of Daily Living (MG‐ADL) total scores (ravulizumab‐ravulizumab, least squares mean [95% CI] change from RCP baseline at week 164: −4.0 [−5.3, −2.8]; p < 0.0001; placebo‐ravulizumab, change from OLE baseline after 138 weeks of treatment: −2.1 [−3.3, −0.9]; p = 0.0005). One hundred and forty‐one out of 160 (88.1%) patients achieved a ≥ 2‐point improvement in MG‐ADL total score, and 59/141 (41.8%) achieved a score of 0 or 1; once achieved, 32/59 (54.2%) sustained this status for > 50% of their remaining time in the study. Similar improvements were observed in Quantitative Myasthenia Gravis and Myasthenia Gravis Quality of Life‐15 revised scores, and Neurological Quality of Life Fatigue subscale scores. Clinical deterioration event rates were reduced in the OLE versus placebo in the RCP. Corticosteroid usage was reduced in the OLE. Ravulizumab was well tolerated; no meningococcal infections were reported.

Conclusion

Ravulizumab demonstrated clinically meaningful and durable efficacy and safety in adults with AChR‐Ab+ gMG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAutoantibodiesMyasthenia GravisReceptors, CholinergicAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodTreatment OutcomeClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

C5ITeculizumabgMGgeneralized myasthenia gravisravulizumab

Substanzen

Antibodies, Monoclonal, HumanizedAutoantibodiesravulizumabReceptors, Cholinergic

Autor:innen und Institutionen

  • University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
  • Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Hôpital Raymond Poincaré, Garches, University Paris Saclay-UVSQ, Garches, France.
  • Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Charité Universitätsmedizin Berlin, Berlin, Germany.
  • London Health Sciences Centre, London, Ontario, Canada.

ORCID-Profile: Masahisa Katsuno, Andreas Meisel, Vera Bril, James F Howard

Förderung

  • Alexion, AstraZeneca Rare Disease
  • Alexion Pharmaceuticals

Zitieren

APA

Vu, T. H., Mantegazza, R., Annane, D., Katsuno, M., Meisel, A., Nicolle, M. W., Bril, V., Aguzzi, R., Frick, G., Howard, J. F., & CHAMPION MG Study Group (2025). Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension. European Journal of Neurology, 32(4). https://doi.org/10.1111/ene.70158

Vancouver

Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, et al. Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension. European Journal of Neurology. 2025;32(4). doi:10.1111/ene.70158

BibTeX
@article{Vu2025,
  author = {Vu, Tuan H and Mantegazza, Renato and Annane, Djillali and Katsuno, Masahisa and Meisel, Andreas and Nicolle, Michael W and Bril, Vera and Aguzzi, Rasha and Frick, Glen and Howard, James F and CHAMPION MG Study Group, CHAMPION MG Study Group},
  title = {Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {4},
  doi = {10.1111/ene.70158}
}
Kostenlos starten →